Educational only. Compounded medications are not FDA-approved. A prescription is required and is not guaranteed. YourHealthRx does not prescribe, dispense, or store patient health information. Clinical services are provided by independent licensed providers. Nothing here is medical advice, dosing guidance, or a treatment recommendation.
PT-141 is another name for bremelanotide, a melanocortin-receptor peptide used in sexual-health care. It acts in the central nervous system, not by changing blood flow the way PDE5 medicines do. That is why people look it up when low desire is the problem they want to understand.
It is not a performance product, and it is not something you start from a search result. A licensed clinician decides whether it belongs in your plan.
Bottom line: PT-141 is a melanocortin-pathway option. The labeled use is specific. Eligibility is clinician-determined.
YourHealthRx framing: education first, then a discreet sexual-health intake if you want a clinician to review whether this pathway is appropriate.
What PT-141 is
Bremelanotide is a synthetic cyclic peptide that activates melanocortin receptors. At treatment-level exposure, MC1R and MC4R are the receptors that matter most. MC4R is found in many areas of the brain. MC1R is found on melanocytes, which is why skin darkening can occur.
The FDA-approved product is Vyleesi (bremelanotide injection). The label says the mechanism by which it improves hypoactive sexual desire disorder (HSDD) in women is unknown. The practical point for patients is simpler: this pathway is about desire signaling in the brain, not about the same vascular mechanism as sildenafil or tadalafil.
YourHealthRx lists PT-141 as an injectable melanocortin-pathway option for sexual-health goals. Listing it is not a guarantee that it is appropriate, available in your state, or that a prescription will be issued.
What it is used for
Vyleesi is FDA-approved for premenopausal women with acquired, generalized HSDD. In plain language, that means low sexual desire that developed after a period of normal desire, shows up across situations and partners, and causes distress. The label also says the low desire should not be explained by another medical or psychiatric condition, relationship problems, or a medication.
The same label states it is not indicated for HSDD in postmenopausal women or in men, and it is not indicated to enhance sexual performance.
That is the approved frame. A clinician may still review PT-141 in a broader sexual-health conversation. Those are different sentences. Approved use is what the label covers. Individual eligibility is what a licensed clinician decides after looking at your history.
Two identical Phase 3 trials (RECONNECT) studied 1,247 premenopausal women with acquired, generalized HSDD. Compared with placebo, bremelanotide showed a statistically significant increase in the Female Sexual Function Index desire domain and a statistically significant decrease in distress about low desire. There was no significant difference in the number of satisfying sexual events, which was a secondary endpoint (Vyleesi prescribing information).
Those results describe a defined population and defined scores. They are not a promise of a specific outcome for any one person.
How it is different from “blood-flow” medicines
PDE5 inhibitors are often the first thing people think of for sexual health. They mainly affect local blood flow.
PT-141 is discussed when the issue is desire, not only physical response. Some people have both. A clinician can sort that out. The useful distinction is mechanism, not a ranking of which medicine is “stronger.”
If low desire is new, sudden, or tied to pain, mood, a new medication, or a relationship change, those facts belong in the intake. They can change whether a melanocortin-pathway option is even the right next step.
What a clinician reviews
Sexual-health decisions are personal. The screening is still medical.
Uncontrolled hypertension and known cardiovascular disease are contraindications on the Vyleesi label. Bremelanotide can raise blood pressure and lower heart rate for several hours after a dose, usually returning toward baseline within about 12 hours. A clinician should consider cardiovascular risk before and during treatment.
Nausea is the most common side effect in the Phase 3 trials (about 40% of treated patients). Flushing, injection-site reactions, headache, and vomiting were also common. Focal skin darkening can occur, more often with more frequent use and in people with darker skin, and it does not always fully reverse.
Bremelanotide can slow stomach emptying and affect some oral medicines. The label advises avoiding it with oral naltrexone products used for alcohol or opioid addiction. Pregnancy is another stop: use effective contraception if you can become pregnant, and discontinue if pregnancy is suspected.
None of that is a reason to hide the option. It is the reason the option sits behind clinician review.
How YourHealthRx approaches it
The sexual-health pathway is discreet. Intake happens with licensed clinical partners, not as a public checkout for a specific compound.
If a clinician prescribes PT-141, it is routed through a licensed pharmacy pathway. Compounded bremelanotide is not the FDA-approved Vyleesi autoinjector. It is still bremelanotide, prepared for an identified patient when a clinician decides that is appropriate. YourHealthRx currently lists PT-141 injectable from $209/mo. That is an “as low as” listed price. Prescriptions are not guaranteed, and the price is not a reason to start.
Follow-up matters here the same way it does on other pathways: how you feel, blood pressure context, nausea, skin changes, and whether the original goal still fits.
FAQ
Is PT-141 the same as Vyleesi?
Vyleesi is the FDA-approved bremelanotide injection. PT-141 is the same active peptide. A compounded injectable is not the brand autoinjector.
Is it only for women?
The approved indication is premenopausal women with acquired, generalized HSDD. A clinician reviews whether it is appropriate in your situation.
Is it like Viagra?
No. It works through melanocortin signaling in the central nervous system. PDE5 medicines work mainly through local blood flow.
Does it work for everyone?
No. Trial results are averages in a defined group. A clinician may also decide it is not a fit because of blood pressure, heart disease, medications, pregnancy plans, or because the desire problem has another cause.
Informational only. This article is educational and does not constitute medical advice, diagnosis, treatment, or a patient-clinician relationship. Compounded medications are not FDA-approved. A prescription is required and is not guaranteed. YourHealthRx does not prescribe, dispense, or store patient health information. Clinical services are provided by independent licensed providers. Nothing here is medical advice, dosing guidance, or a treatment recommendation.
Source: Vyleesi (bremelanotide) prescribing information, DailyMed